Articles tagged "Rejection"

2022 American Transplant Congress
Noninvasive Biomarkers for Allograft Monitoring After Intestinal Transplantation: Promising Early Results from a Novel Peptide, REG3α
C. P. Smullin¹, R. S. Venick², E. A. Marcus², B. V. Naini³, D. G. Farmer⁴
¹David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Pediatrics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Pathology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ⁴Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
*Purpose: There is an urgent need for the discovery and application of noninvasive biomarkers to detect allograft rejection after intestinal transplantation (ITx). Calprotectin and citrulline…
2022 American Transplant Congress
Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series
B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹
¹Nephrology, University of Washington, Seattle, WA, ²Surgery, University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA
*Purpose: The optimal treatment for chronic active antibody-mediated rejection (ca-AMR) remains unclear. Tocilizumab (TCZ), a monoclonal antibody against IL-6, has been proposed in ca-AMR treatment…
2022 American Transplant Congress
The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant
M. Galle, P. Stracener, K. Warrior, J. Lyons
Loyola University Medical Center, Maywood, IL
*Purpose: To evaluate the impact of antibody mediated rejection (AMR) treatment with rituximab combined with bortezomib vs. rituximab alone on patient survival, graft survival, and…
2022 American Transplant Congress
Using a Unique Repository of Pancreas Transplant Biopsies to Validate the Tissue Common Response Module (tCRM) Score as a Tool to Assess the Severity of Pancreas Transplant Rejection
Y. Kelly¹, A. Zarinsefat¹, R. Meier², M. Sarwal¹, P. Stock¹, Z. Laszik¹, T. Sigdel¹
¹University of California, San Francisco, San Francisco, CA, ²University of Maryland Medical Center, Baltimore, MD
*Purpose: Analysis of transcriptional data from kidney, heart, liver, and lung transplant rejection led to development of the tissue Common Response Module (tCRM) score based…
2022 American Transplant Congress
Tracking of Donor Reactive T Cell Clones Can Be Used to Diagnose or Even Predict Kidney Transplant Rejection
J. M. Mathew¹, Y. Sambandam¹, M. Kandpal¹, J. He¹, G. Perottino¹, B. Banbury², P. Fields², L. Gallon¹, J. R. Leventhal¹
¹Northwestern University, Chicago, IL, ²Adaptive Biotechnologies, Seattle, WA
*Purpose: Transplant (Tx) rejection currently requires an invasive biopsy for diagnosis. We have tested if serial quantitation of donor reactive T cell clones (DRTC) can…
2022 American Transplant Congress
Prospective Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) in Monitoring Response to Anti-Rejection Treatment in Kidney Transplant Recipients with Indication Biopsy
L. Benning¹, A. Fink², F. Kälble¹, C. Speer¹, C. Nusshag¹, M. Zeier¹, C. Süsal³, C. Morath¹, T. Tran²
¹Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany, ²Transplantation Immunology, Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany, ³Transplant Immunology Research Center of Excellence, Koç University Hospital, Istanbul, Turkey
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a marker of allograft injury in kidney transplant recipients (KTR). Little is known about the possible use of dd-cfDNA…
2022 American Transplant Congress
Interleukin-31 (IL-31) and Leukemia Inhibitory Factor (LIF) Are Upregulated in Acute Rejection of Kidney Allograft
I. Striz, L. Krupickova, M. Fialova, M. Novotny, E. Cecrdlova, O. Viklicky
Institute for Clinical and Experimental Medicine, Praha, Czech Republic
*Purpose: Interleukin-31 (IL-31) and leukemia inhibitory factor (LIF) belong to the IL-6 cytokine family clustered by their pro-inflammatory properties and a shared signaling pathway of…
2022 American Transplant Congress
Single Cell Transcriptomics Reveal Allograft Immune Cell Patterns Associated with Histological Features of Acute Cellular Rejection in Liver Transplantation
L. Tran¹, A. Zahorchak¹, C. Macedo¹, T. Tabib², F. Lakkis³, A. Humar¹, D. Metes¹, A. Thomson¹
¹Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh Medical Center - Thomas E. Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: Development of successful tolerance induction strategies using immune cell-based therapies in transplantation depends on improved understanding of the local intra-graft cellular milieu that underlies…
2021 American Transplant Congress
Significance of Repeated 1r Rejections in Heart Transplantation
C. Hsueh¹, L. Wilson², L. Bow², L. Bellumkonda²
¹Yale New Haven Hospital, New Haven, CT, ²Yale University School of Medicine, New Haven, CT
*Purpose: 1R rejection is commonly seen in routine post-transplant biopsies. While presence of occasional 1R rejection is not considered to be detrimental, the significance of…
2021 American Transplant Congress
Donor-derived Cell-free DNA Distinguishes Acute Rejection from Other Causes of Graft Injury in Liver Transplant Recipients
J. Levitsky¹, M. Miller², R. Sinha², E. Bixler², A. Al-Turck², J. Weems², M. Altrich², S. Kleiboeker², M. Abecassis³
¹Gastroenterology & Hepatology; Comprehensive Transplant Center, Northwestern University, Chicago, IL, ²Viracor Eurofins, Lees Summit, MO, ³University of Arizona College of Medicine Tucson, Tucson, AZ
*Purpose: The donor derived cell-free DNA (ddcfDNA) has emerged as strong biomarker for allograft injury, where the fraction of ddcfDNA is reported to increase in…